<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INTERFERON ALFACON-1</span><br/>(in-ter-fer'on al'fa-con)<br/><span class="topboxtradename">Infergen<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>9 mcg, 15 mcg injection</p>
<h1><a name="action">Actions</a></h1>
<p>DNA recombinant Type 1 interferon. Its antiviral, antiproliferative, and natural killer (NK) cell activity is five times greater
         than interferon alpha-2a or interferon alpha-2b.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Normalization of ALT level and serum HCV RNA 
      </p><h1><a name="uses">Uses</a></h1>
<p>Treatment of chronic hepatitis C.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to alpha interferons or <i>E.coli</i> products; patients with decompensated liver disease such as jaundice, ascites, etc.; pregnancy (category C), lactation, children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of severe psychiatric disorder, depression, or suicidal ideation; pre-existing cardiac disease, myelosuppression,
         previous hypersensitivity to interferon therapy; history of endocrine disorders; ophthalmic disorders or autoimmune disorders.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Hepatitis C</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 9 mcg 3 times/wk times 24 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Allow at least 24 h to elapse between doses of interferon alfacon-1.</li>
<li>Give only one dose per vial or per prefilled syringe. Enter each vial only once. Discard unused portion of a vial or prefilled
            syringe immediately.
         </li>
<li>Initiate treatment only if acceptable baseline lab values are obtained: Platelet count <img src="../images/special/greaterorequal.gif"/>75
            <small>x</small> 10<sup>9</sup>/L, Hgb <img src="../images/special/greaterorequal.gif"/>100 g/L, ANC <img src="../images/special/greaterorequal.gif"/>1500
            <small>x</small> 10<sup>6</sup>/L, serum creatinine 25 g/L, bilirubin WNL, TSH,
            and T<sub>4</sub> WNL.
         </li>
<li>Store vials and syringes at 2°8° C (36°46° F). Avoid direct sunlight and vigorous shaking.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Asthenia, headache, fatigue, fever, chills, injection site reaction (pain, edema, hemorrhage, inflammation), pain, myalgia,
         arthralgia,</span> increased sweating. <span class="typehead">CNS:</span> <span class="speceff-common">Insomnia, depression, dizziness, paresthesia nervousness, depression, anxiety,</span> agitation. <span class="typehead">CV:</span> Hypertension, palpitation. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, diarrhea, abdominal pain, anorexia, vomiting, dyspepsia,</span> constipation, flatulence, toothache, hemorrhoids, weight loss, hepatotoxicity. <span class="typehead">Hematologic:</span> <span class="speceff-common">Granulocytopenia, thrombocytopenia, leukopenia,</span> ecchymosis, lymphadenopathy, lymphocytosis. <span class="typehead">Respiratory:</span> <span class="speceff-common">Cough, bronchitis, dyspnea, pneumonia, rhinitis,</span> pharyngitis. <span class="typehead">Skin:</span> <span class="speceff-common">Alopecia, rash,</span> dry skin, <span class="speceff-common">pruritus,</span> erythema. <span class="typehead">Urogenital:</span> Dysmenorrhea, vaginitis, menstrual disorder. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 2436 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report any of the following S&amp;S immediately: Depression, suicidal ideation, suicide attempt, or other indications
            of psychiatric disturbance.
         </li>
<li>Withhold drug and notify physician if symptoms of hepatic decompensation such as jaundice or ascites develop. Withhold drug
            and notify physician if any other severe adverse reaction occurs.
         </li>
<li>Lab tests: Baseline, 2 wk after initiation of therapy, and periodically thereafter: platelet count, Hgb and Hct, WBC and ANC,
            serum creatinine, serum albumin, bilirubin, thyroid function, and triglyceride; periodic ALT to determine liver functions.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any signs of psychiatric disturbance including depression, thoughts of suicide, nervousness, anxiety, agitation,
            apathy, or significant mood swings to physician.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>